Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adolescent

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    716 result(s) found for: Adolescent. Displaying page 1 of 36.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-005677-23 Sponsor Protocol Number: CFTY720D2311 Start Date*: 2013-04-02
    Sponsor Name:Novartis Farma
    Full Title: A two-year, double-blind, randomized, multicenter, active controlled study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ...
    Medical condition: Relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing) LT (Ongoing) SK (Trial now transitioned) LV (Ongoing) ES (Ongoing) DE (Trial now transitioned) BG (Completed) PL (Completed) AT (Completed) NL (Completed) SE (Ongoing) GB (GB - no longer in EU/EEA) RO (Ongoing) EE (Completed) FR (Trial now transitioned) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001176-42 Sponsor Protocol Number: KVD900-302 Start Date*: 2022-09-30
    Sponsor Name:KalVista Pharmaceuticals Ltd
    Full Title: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients with He...
    Medical condition: Hereditary Angioedema Type I or II
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004850 10080956 Hereditary angioedema type I LLT
    26.0 100000004850 10080960 Hereditary angioedema type II LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) BG (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) IT (Ongoing) DE (Ongoing) PT (Trial now transitioned) SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000844-25 Sponsor Protocol Number: R668-EE-1774 Start Date*: 2019-10-21
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis (EoE)
    Medical condition: Eosinophilic Esophagitis (EoE)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10064212 Eosinophilic oesophagitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PT (Completed) BE (Completed) IT (Completed) ES (Restarted)
    Trial results: View results
    EudraCT Number: 2015-004889-28 Sponsor Protocol Number: FFR113342 Start Date*: 2016-12-21
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent...
    Medical condition: Rhinitis, Allergic, Perennial
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-005830-63 Sponsor Protocol Number: 0485-CL-0004 Start Date*: 2009-10-30
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects with Moderate to Severe Psoriasis
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003016-12 Sponsor Protocol Number: TMC114FD2HTX1003 Start Date*: 2019-01-02
    Sponsor Name:Janssen Sciences Ireland UC
    Full Title: A study to assess the acceptability/swallowability of DRV-containing FDC tablets in HIV-1 infected adolescents, using matching placebo tablets. Rezolsta: EMEA-001280-PIP01-12-M01 Decision: P/0...
    Medical condition: Human immunodeficiency virus (HIV) Type 1
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-005716-64 Sponsor Protocol Number: 112233020781 Start Date*: 2008-08-28
    Sponsor Name:Universitätsklinik für Psychiatrie des Kindes- und Jugendalters, AKH Wien, Medizinische Universität
    Full Title: Elevated elimination rates of quetiapine in adolescent patients with schizophrenia (ICD 10: F 20.-), bipolar affective disorder (ICD 10: F 31.-), disorders in impulse control with current PTSD (ICD...
    Medical condition: schizophrenia (ICD 10: F 20.-), bipolar affective disorder (ICD 10: F 31.-), disorders of impulse control with current PTSD (ICD 10: F 43.1) or personality disorder (ICD 10: F 60.-).
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004155-43 Sponsor Protocol Number: PA-CL-PED-01 Start Date*: 2016-05-04
    Sponsor Name:Vifor Fresenius Medical Care Renal Pharma France
    Full Title: An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and...
    Medical condition: Control of serum phosphorus levels in paediatric and adolescent subjects with chronic kidney disease (CKD).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10076411 Chronic kidney disease stage 4 LLT
    20.0 100000004857 10076412 Chronic kidney disease stage 5 LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-004891-36 Sponsor Protocol Number: NN7415-4307 Start Date*: 2019-11-20
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B without inhibitors
    Medical condition: Haemophilia A Haemophilia B
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10018938 Haemophilia A (Factor VIII) LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: DK (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) SK (Prematurely Ended) DE (Trial now transitioned) BG (Temporarily Halted) GB (GB - no longer in EU/EEA) FR (Ongoing) PT (Trial now transitioned) HR (Ongoing) HU (Ongoing) LT (Trial now transitioned) EE (Ongoing) IT (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2021-003253-36 Sponsor Protocol Number: LBS-008-CT03 Start Date*: Information not available in EudraCT
    Sponsor Name:Belite Bio, Inc
    Full Title: Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects
    Medical condition: Stargardt Disease
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Ongoing) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001767-30 Sponsor Protocol Number: A3051070 Start Date*: 2007-07-27
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017, United States
    Full Title: PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE MULTIPLE-DOSE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF VARENICLINE IN HEALTHY ADOLESCENT SMOKERS
    Medical condition: Smoking cessation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053325 Smoking cessation therapy LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Not Authorised) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000839-33 Sponsor Protocol Number: LP0053-1108 Start Date*: 2016-03-23
    Sponsor Name:LEO Pharma A/S
    Full Title: Safety and Effect of LEO 90100 aerosol foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) with Plaque Psoriasis A phase 2 trial evaluating the safety and e...
    Medical condition: Plague Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002780-42 Sponsor Protocol Number: TR701-111 Start Date*: 2015-06-29
    Sponsor Name:Trius Therapeutics [...]
    1. Trius Therapeutics
    2. Cubist Pharmaceuticals, Inc
    Full Title: A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 Year Old Ad...
    Medical condition: Acute bacterial skin and skin structure infections
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022891 - Investigations 10040879 Skin investigations HLGT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004729-34 Sponsor Protocol Number: NOV-FR04 Start Date*: 2019-05-21
    Sponsor Name:Medical Center- Universtíty of Freiburg Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics
    Full Title: Effects of transdermal estrogen on Bone Mass in adolescent female patients with Anorexia nervosa (AN) – a placebo-controlled, double-blind, randomized, interventional study
    Medical condition: Anorexia nervosa
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004353-14 Sponsor Protocol Number: NN8022-4180 Start Date*: 2016-08-15
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of liraglutide for weight management in pubertal adolescent subjects with obesity. 56-week, double-blind, randomised, parallel-group, placebo-controlled multi-national trial followed by a 26...
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    19.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001383-28 Sponsor Protocol Number: M18-891 Start Date*: 2018-10-30
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
    Medical condition: Moderate and Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) DK (Trial now transitioned) PT (Ongoing) CZ (Trial now transitioned) DE (Ongoing) FR (Trial now transitioned) AT (Trial now transitioned) HU (Ongoing) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) NL (Trial now transitioned) GR (Ongoing) BG (Trial now transitioned) ES (Ongoing) IT (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-005143-33 Sponsor Protocol Number: LP0162-1334 Start Date*: 2018-11-23
    Sponsor Name:LEO Pharma A/S
    Full Title: A randomised, double-blind, placebo-controlled, parallel-group, multi-centre trial to evaluate the efficacy, safety, and tolerability of tralokinumab monotherapy in adolescent subjects with moderat...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) DE (Completed) NL (Completed) BE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2023-000924-13 Sponsor Protocol Number: VAN00010 Start Date*: 2023-12-21
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity study to assess Pentavalent Meningococcal ABCYW Vaccine formulations in Adults (18 to 25 years of age) and Adolescents (10 to 17 yea...
    Medical condition: Bacterial infections and mycoses
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2005-002928-34 Sponsor Protocol Number: 021049 Start Date*: 2006-04-24
    Sponsor Name:NV Organon
    Full Title: A randomized, assessor-blind, dose-ranging, phase IIIB, multicenter trial comparing the intubating conditions and time course of block of three different intubating doses (0.45 mg/kg, 0.6 mg/kg, an...
    Medical condition: Not applicable
    Disease:
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000685-12 Sponsor Protocol Number: MC2-01-C6 Start Date*: Information not available in EudraCT
    Sponsor Name:MC2 Therapeutics Ltd
    Full Title: A Multicentre, Open-label, Single-group Maximal Use Trial, Evaluating the Safety and Pharmacokinetic Profile of the Active Ingredients and their Metabolites after application of MC2-01 Cream in Ado...
    Medical condition: Extensive Psoriasis Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 06:50:45 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA